Radiation and concurrent carboplatin administration in locally advanced head and neck cancer
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Nikolaou, A. | en |
dc.contributor.author | Kalogera-Fountzila, Anna | en |
dc.contributor.author | Tzitzikas, J. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Makrantonakis, P. | en |
dc.contributor.author | Samantas, E. | en |
dc.contributor.author | Karpasitis, N. | en |
dc.contributor.author | Bacoyiannis, Charalambos | en |
dc.contributor.author | Synodinou, M. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Vritsios, A. | en |
dc.contributor.author | Daniilidis, J. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Nikolaou, A. | en |
dc.creator | Kalogera-Fountzila, Anna | en |
dc.creator | Tzitzikas, J. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Makrantonakis, P. | en |
dc.creator | Samantas, E. | en |
dc.creator | Karpasitis, N. | en |
dc.creator | Bacoyiannis, Charalambos | en |
dc.creator | Synodinou, M. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Vritsios, A. | en |
dc.creator | Daniilidis, J. | en |
dc.date.accessioned | 2018-06-22T09:53:07Z | |
dc.date.available | 2018-06-22T09:53:07Z | |
dc.date.issued | 1995 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41671 | |
dc.description.abstract | Aims and Background: To improve local control in patients with locally advanced inoperable head and neck cancer we administered carboplatin concurrently with radiation. Methods: Thirty-nine patients entered the study. There were 35 men and 4 women with a median age of 58 years (range, 24-74) and a median performance status of 90 (range, 60-100) of the Karnofsky scale. The primary site included nasopharynx (5 patients), oropharynx (n = 10), hypopharynx (n = 5), larynx (n = 12), oral cavity (n = 2), paranasal sinuses (n = 3), salivary glands (n = 1) and unknown (n = 1). Histology was squamous cell carcinoma in all cases. All patients were irradiated with a 60Co unit. According to the protocol, they should receive 66-70 Gy to the tumor area and 45 Gy to the tumor-free area of the neck. Carboplatin was administered at a dose of 400 mg/m2 on days 2, 22 and 42. Results: Totally, 112 cycles of carboplatin were administered, of which 106 (95%) were at full dose. Median dose intensity of carboplatin actually delivered was 170 mg/m2/week (range, 57-200). All patients were irradiated, although only 30 (77%) received >66 Gy. After the completion of combined treatment, 23 (59%, 95% C.I. 42-74%) achieved a CR and 10 (26%, 95% C.I. 13-42%) a PR. Grade 3-4 myelotoxicity was noticed in 60% of the patients. Other grade 3-4 toxicities included stomatitis (13%), dysphagia (5%) and weight loss (3%). Median time to progression was 18 months (range, 2-25). Conclusions: Radiation and concurrent administration of carboplatin determined a high CR rate in patients with HNC, although the superiority of this combined modality approach over radiation alone has to be proven in phase III trials. | en |
dc.language.iso | eng | en |
dc.source | Tumori | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Bleomycin | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Carboplatin | en |
dc.subject | Chemotherapy | en |
dc.subject | Neoplasm staging | en |
dc.subject | Anemia | en |
dc.subject | Bone marrow suppression | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Ondansetron | en |
dc.subject | Stomatitis | en |
dc.subject | Treatment outcome | en |
dc.subject | Survival analysis | en |
dc.subject | Dexamethasone | en |
dc.subject | Male | en |
dc.subject | Adjuvant | en |
dc.subject | Intravenous drug administration | en |
dc.subject | Side effect | en |
dc.subject | Vomiting | en |
dc.subject | Radiotherapy | en |
dc.subject | Nausea | en |
dc.subject | Complication | en |
dc.subject | Dysphagia | en |
dc.subject | Weight reduction | en |
dc.subject | Chemotherapy | en |
dc.subject | Multimodality cancer therapy | en |
dc.subject | Head and neck cancer | en |
dc.subject | Head and neck neoplasms | en |
dc.subject | Radiation | en |
dc.subject | Patient compliance | en |
dc.title | Radiation and concurrent carboplatin administration in locally advanced head and neck cancer | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 81 | |
dc.description.issue | 5 | |
dc.description.startingpage | 354 | |
dc.description.endingpage | 358 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Kalogera-Fountzila, Anna [0000-0002-6801-3129] | |
dc.gnosis.orcid | 0000-0002-2195-9961|0000-0002-6801-3129 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |